Ipsen
Also known as: Biomeasure Inc, Ipsen Group | Ipsen | IPSEN | Ipsen Biopharmaceuticals | Ipsen Biopharmaceuticals, Inc. | IPSEN BIOPHARMACEUTICALS INC | Ipsen Biopharm Limited | IPSEN BIOPHARM LTD | Ipsen (formerly Tercica) | Ipsen (formerly Tercica, Inc.) | IPSEN INC | Ipsen Innovation | IPSEN PHARMA | IPSEN pharmaceutical company, Boulogne-Billancourt, France | IPSEN PHARMA S.A.S
Highest phase reached
Phase 4
First clinical trial
Jan 1, 1990First marketed drug
Aug 30, 2005First NDA
Aug 30, 2007Last known activity
Nov 10, 2025
Timeline
1920s
- Jan 1, 1929
Ipsen— Founded
2010s
- Jul 15, 2013
Syntaxin— Acquired
- Feb 24, 2015
Canbex Therapeutics Ltd— Acquired
- May 20, 2015
OctreoPharm Sciences— Acquired
- Oct 22, 2015
irinotecan— Marketing Organization
- Oct 22, 2015
irinotecan— NDA Secondary Org
- Apr 18, 2019
Clementia Pharmaceuticals Inc.— Acquired
2020s
- Jun 27, 2022
Epizyme, Inc.— Acquired
- Jan 9, 2023
Albireo— Acquired
- Jun 10, 2024
elafibranor— NDA Organization
- Oct 22, 2025
ImCheck Therapeutics— Acquired
Drugs by trial phase (122 distinct, 311 trials)
Phase 4 (10 own, 2 via acquisition)
Phase 3 (23 own, 11 via acquisition)
Phase 2 (35 own, 23 via acquisition)
Phase 1 (7 own, 11 via acquisition)
Indications
Approved for
Studied for
- Acromegaly
- Adenocarcinoma
- Adenoma, Islet Cell
- Alzheimer Disease
- Ataxia
- Back Pain
- Biliary Tract Neoplasms
- Blepharospasm
- Bone Neoplasms
- Brain Injuries
- Brain Injuries, Traumatic
- Breast Neoplasms
- Cachexia
- Carcinoid Heart Disease
- Carcinoid Tumor
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Islet Cell
- Carcinoma, Neuroendocrine
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carotid Body Tumor
- Cerebellar Ataxia
- Cerebral Palsy
- Cholangiocarcinoma
- Cognitive Dysfunction
- Colorectal Neoplasms
- Constipation
- Cysts
- Dementia
- Diarrhea
- Digestive System Diseases
- Digestive System Neoplasms
- Disease
- Dumping Syndrome
- Dwarfism
- Dystonia
- Dystonic Disorders
- Endocrine Gland Neoplasms
- Endometrial Neoplasms
- Endometriosis
- Enuresis
- Esophageal Neoplasms
- Eye Diseases
- Failure to Thrive
- Fasciitis
- Fasciitis, Plantar
- Fibromyalgia
- Fissure in Ano
- Fistula
- Fractures, Bone
- Friedreich Ataxia
- Gastrointestinal Diseases
- Gastrointestinal Neoplasms
- Gonadal Dysgenesis
- Graves Ophthalmopathy
- Growth Disorders
- Hallux Valgus
- Headache
- Heart Diseases
- Hemifacial Spasm
- Hemophilia A
- Hepatomegaly
- Huntington Disease
- Intestinal Diseases
- Intestinal Neoplasms
- Intestinal Obstruction
- Kidney Diseases
- Laron Syndrome
- Liver Diseases
- Liver Neoplasms
- Low Back Pain
- Lung Neoplasms
- Lymphocele
- Lymphoma
- Malignant Carcinoid Syndrome
- Memory Disorders
- Migraine Disorders
- Migraine without Aura
- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Muscle Spasticity
- Muscular Dystrophies
- Muscular Dystrophy, Duchenne
- Myofascial Pain Syndromes
- Nausea
- Neoplasm Metastasis
- Neoplasms
- Neoplastic Cells, Circulating
- Nervous System Diseases
- Neuroendocrine Tumors
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Paraganglioma
- Paresis
- Parkinson Disease
- Pelvic Pain
- Peritoneal Neoplasms
- Pheochromocytoma
- Pituitary Diseases
Marketed drugs (8)
Subsidiaries (10 direct, 11 total across the full acquisition tree)
Recent trials (50)
- NCT04225429OfficialN/A—
- NCT07213830OfficialPhase 1/Phase 2Nov 10, 2025
- NCT07213830Lead sponsorPhase 1/Phase 2Nov 10, 2025
- NCT07213817OfficialPhase 1/Phase 2Oct 30, 2025
- NCT07213817Lead sponsorPhase 1/Phase 2Oct 30, 2025
- NCT06937931OfficialPhase 2Jun 30, 2025
- NCT06937931Lead sponsorPhase 2Jun 30, 2025
- NCT06934057CollaboratorPhase 4May 16, 2025
- NCT06692452CollaboratorPhase 2Apr 30, 2025
- NCT06824701CollaboratorPhase 1Mar 31, 2025
- NCT06835387CollaboratorPhase 2Mar 31, 2025
- NCT06833008Lead sponsorPhase 1/Phase 2Mar 14, 2025
- NCT06833008OfficialPhase 1/Phase 2Mar 14, 2025
- NCT06908954OfficialPhase 1Mar 14, 2025
- NCT06908954Lead sponsorPhase 1Mar 14, 2025
Details
- Founded
- Boulogne, FR Jan 1, 1929
- First NDA
- Aug 30, 2007
- Last known activity
- Nov 10, 2025
Designations held
- Orphan drug
- Priority review
- Breakthrough therapy
- Accelerated approval